ClinicalTrials.gg

Program

dotinurad

Also written as “FYU-981”, “Dotinurad” and “FYU-981, (Oral single dosing)”.

Its studies are mostly in Gout · Hyperuricemia · Hepatic Insufficiency · Renal Insufficiency, led by 5 companies.

Furthest: phase 3, since Dec 28, 201622 company-led studies, 3 open or runningNext primary completion: Jul 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fuji Yakuhin110 open or runningphase 3since Dec 28, 2016Jan 16, 2015none ahead
Mochida Pharmaceutical50 open or runningphase 3since Dec 10, 2017Sep 20, 2017none ahead
Crystalys Therapeutics33 open or runningphase 3since Jul 22, 2025Jul 22, 2025Jul 2027phase 2 · NCT07535034
Eisai20 open or runningphase 3since Aug 11, 2021Aug 11, 2021none ahead
Urica Therapeutics10 open or runningphase 2since Sep 7, 2023Sep 7, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Jan 16, 2015.

  1. Jul 29, 2015Phase 2 study in HealthyFuji Yakuhin · NCT02515864 · 48 enrolled · Japan
  2. Jul 15, 2016Phase 2 study in HyperuricemiaFuji Yakuhin · NCT02837198 · 24 enrolled · Japan
  3. Sep 12, 2016Phase 2 study in Healthy Male SubjectsFuji Yakuhin · NCT02901366 · 6 enrolled · Japan
  4. Dec 28, 2016Phase 3 study in Hyperuricemia With or Without GoutFuji Yakuhin · NCT03006445 · 330 enrolled · Japan
  5. Mar 29, 2017Phase 3 study in Hyperuricemia With or Without GoutFuji Yakuhin · NCT03100318 · 201 enrolled · Japan
  6. Sep 20, 2017Mochida Pharmaceutical's first study: phase 1 study in Hepatic InsufficiencyNew to Mochida PharmaceuticalMochida Pharmaceutical · NCT03306667 · 24 enrolled · Japan
  7. Nov 19, 20172 phase 1 studies in HealthyMochida Pharmaceutical · NCT03350386, NCT03350373
  8. Dec 10, 2017Phase 1 study in Hyperuricemia With or Without GoutMochida Pharmaceutical · NCT03375632 · 26 enrolled · Japan
  9. Dec 10, 2017Phase 3 study in Hyperuricemia With or Without GoutMochida Pharmaceutical · NCT03372200 · 203 enrolled · Japan
  10. Aug 11, 2021Eisai's first study: phase 3 study in GoutNew to EisaiEisai · NCT05007392 · 451 enrolled · China
  11. Feb 18, 2022Phase 1 study in Healthy VolunteersEisai · NCT05278676 · 26 enrolled · China
  12. Sep 7, 2023Urica Therapeutics's first study: phase 2 study in GoutNew to Urica TherapeuticsUrica Therapeutics · NCT06056570 · 20 enrolled · United States
  13. Jul 22, 2025Crystalys Therapeutics's first studies: 2 phase 3 studiesNew to Crystalys TherapeuticsCrystalys Therapeutics · NCT07089888, NCT07089875
  14. Apr 10, 2026Phase 2 study in GoutCrystalys Therapeutics · NCT07535034 · 90 planned · United States

Ahead

  1. Jul 2027Primary completion: phase 2 study in GoutCrystalys Therapeutics · NCT07535034
  2. Nov 29, 2027Primary completion: phase 3 study in GoutCrystalys Therapeutics · NCT07089875
  3. Dec 31, 2027Primary completion: phase 3 study in HyperuricemiaCrystalys Therapeutics · NCT07089888

TargetBeta

SLC22A12 →read by rule
“Solute carrier family 22 member 12 inhibitor”ChEMBL 37, by rule

Other programs on SLC22A12

ProgramCompanyFurthest phaseStudies
ruzinuradruleJiangsu HengRui Medicinephase 320

Studies

All 22 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07535034Gout · United States2RecruitingCrystalys TherapeuticsJul 202790
NCT07089888Hyperuricemia · United States3RecruitingCrystalys TherapeuticsDec 31, 2027250
NCT07089875Gout · United States, Poland, Spain3RecruitingCrystalys TherapeuticsNov 29, 2027500
NCT06056570Gout · United States2CompletedUrica TherapeuticsJun 27, 202420
NCT05278676Healthy Volunteers · China1CompletedEisaiDec 13, 202226
NCT05007392Gout · China3CompletedEisaiJun 14, 2023451
NCT03375632Hyperuricemia With or Without Gout · Japan1CompletedMochida PharmaceuticalMay 29, 201826
NCT03372200Hyperuricemia With or Without Gout · Japan3CompletedMochida PharmaceuticalJun 4, 2018203
NCT03350386Healthy · Japan1CompletedMochida PharmaceuticalDec 5, 201712
NCT03350373Healthy · Japan1CompletedMochida PharmaceuticalNov 29, 201712
NCT03306667Hepatic Insufficiency · Japan1CompletedMochida PharmaceuticalJun 20, 201824
NCT03100318Hyperuricemia With or Without Gout · Japan3CompletedFuji YakuhinApr 25, 2018201
NCT03006445Hyperuricemia With or Without Gout · Japan3CompletedFuji YakuhinAug 23, 2018330
NCT02901366Healthy Male Subjects · Japan2CompletedFuji YakuhinJan 20176
NCT02837198Hyperuricemia · Japan2CompletedFuji YakuhinAug 201724
NCT02515864Healthy · Japan2CompletedFuji YakuhinMar 201648
NCT02416167Hyperuricemia · Japan2CompletedFuji YakuhinMay 2016200
NCT02348333Healthy · Japan1CompletedFuji YakuhinNov 201318
NCT02348307Healthy · Japan1CompletedFuji YakuhinJun 201354
NCT02344875Healthy · Japan1CompletedFuji YakuhinJun 201424
NCT02344862Hyperuricemia · Japan2CompletedFuji YakuhinJul 201480
NCT02347046Renal Insufficiency · Japan1CompletedFuji YakuhinMar 201518

How it is read

Names in the registry

  • “FYU-981”, 10 entries
  • “Dotinurad”, 5 entries
  • “FYU-981, (Oral single dosing)”, 3 entries
  • “dotinurad”, 1 entry
  • “dotinurad + allopurinol”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.